New Chalcone Incorporated Structurally Modified Pyridine‐Pyrimidine Derivatives as Anticancer Agents: Their Design, Synthesis, and in‐vitro Evaluation

Abstract

Chalcone‐incorporated pyridine‐pyrimidines i.e. derivatives of (5‐(6‐(pyrimidin‐5‐yl)pyridin‐3‐yl)thiophen‐2‐yl)prop‐2‐en‐1‐one were synthesized and their structures were confirmed by analytical techniques. In addition, all the derivatives were examined for their capacity to fight against cancer towards four cell lines, including breast (MCF‐7), prostate (DU‐145 and PC3), and lung (A549) by utilizing the MTT technique and the clinically used chemotherapy medication, etoposide serving as a positive reference. All these results were expressed in IC50 µM, and values of synthesized compounds are compared with a reference drug, showing values ranging from 1.97 ± 0.45 µM to 3.08 ± 0.135 µM. Among those, a few compounds 10(a‐e) demonstrated strong activities with corresponding cell lines.